During pediatric advanced life support (PALS), what is the correct medication for treating ventricular fibrillation in a child?
A Adenosine
B Amiodarone
C Atropine
D Epinephrine
The correct answer and Explanation is :
The correct medication for treating ventricular fibrillation (VF) in a child during Pediatric Advanced Life Support (PALS) is B: Amiodarone.
Explanation:
Ventricular fibrillation is a life-threatening arrhythmia that requires immediate intervention. In pediatric patients, the standard approach to managing VF during cardiac arrest includes high-quality cardiopulmonary resuscitation (CPR) and the administration of medications after defibrillation attempts.
Amiodarone is an antiarrhythmic drug that is effective in treating VF and pulseless ventricular tachycardia (VT). It works by stabilizing the cardiac cell membranes and prolonging the action potential and refractory period in myocardial tissue. In children, the recommended dose of amiodarone for refractory VF or pulseless VT is 5 mg/kg, which can be repeated if necessary.
In contrast, adenosine (A) is primarily used for converting supraventricular tachycardia and is not effective for VF. Atropine (C) is an anticholinergic agent used to treat bradycardia and is not indicated for VF. Epinephrine (D), while crucial in the management of cardiac arrest, does not directly address the rhythm of VF but is used to improve coronary perfusion pressure and increase the likelihood of restoring a perfusing rhythm. The standard protocol involves administering epinephrine every 3-5 minutes during the resuscitation efforts.
In summary, while both amiodarone and epinephrine are used during cardiac arrest management, amiodarone is the specific medication recommended for the treatment of ventricular fibrillation in children. Following the administration of amiodarone, if VF persists, further defibrillation and additional doses may be necessary until the rhythm is stabilized. Proper training and adherence to PALS guidelines are essential for effective emergency response in pediatric patients experiencing cardiac arrest.